A blood-brain barrier on a chip to study drugs against Alzheimer’s

by IBEC - Institut de Bioenginyeria de Catalunya

A study led by the Institute of Bioengineering of Catalonia (IBEC) describes the development of an organ-on-a-chip that mimics the human blood-brain barrier. With this system, researchers can study th...

Read more

ORYZON announces positive results from planned interim analysis of PORTICO, a Phase 2b adaptive trial in Borderline Personality Disorder

by Oryzon Genomics

Oryzon Genomics S.A., announced today positive outcome from its planned, prespecified interim analysis of its Phase 2b trial, PORTICO, with vafidemstat for borderline personality disorder (BPD). These...

Read more

Asthma: a chronic but controllable disease

by Fundació Clínic per a la Recerca Biomèdica

Asthma is a disease that is currently without a cure. Modern treatments make it possible to manage asthma and to help most patients lead a normal life without limitations.

Read more

Kala Pharmaceuticals Receives FDA Fast Track Designation for KPI-012, a Human MSC-S Therapy for Persistent Corneal Epithelial Defect

by Ysios Capital

Kala Pharmaceuticals today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for Kala’s human mesenchymal stem cell secretome (MSC-S) therapy (KPI-012) fo...

Read more

Peaches Biotech recibe 598.000 euros del CDTI por su proyecto PRS de terapias avanzadas

by Peaches Biotech

Peaches Biotech ha sido considerada como altamente innovadora por el Centro para el Desarrollo Tecnológico y la Innovación (CDTI), dependiente del Ministerio de Ciencia e Innovación, al aprobar el ...

Read more

Results of the ROAR basket study: the efficacy and safety of combined tumor-agnostic therpy in pacients with BRAFV6ooE-murated rare cancers

by VHIO

Encouraging efficacy and safety results of the phase II ROAR basket study support tumor-agnostic therapy in patients with rare cancers and suggest that genetic testing and tumor profiling should be in...

Read more

Primer ‘mapa’ genómico del parásito causante de la babesiosis

by DiCYT - Agencia Iberoamericana para la Difusión de la Ciencia y la Tecnología

Un equipo del Centro Nacional de Microbiología (CNM) del Instituto de Salud Carlos III (ISCIII) ha participado en una investigación internacional que ha desvelado la primera secuencia completa y la ...

Read more

Minoryx presents positive interim results from NEXUS registration study for leriglitazone targeting pediatric ALD patients with cerebral adrenoleukodystrophy (cALD)

by Ysios Capital

Minoryx Therapeutics today announces 24-week interim results from NEXUS. This open label registration-enabling clinical trial is assessing the safety and efficacy of lead candidate leriglitazone, a no...

Read more

SparingVision Presents Progress of its Lead Gene Therapy Program SPVN06 at ARVO 2023

by Ysios Capital

SparingVision, a clinical-stage genomic medicine company developing vision-saving treatments for ocular diseases, shares progress in its lead gene therapy program, SPVN06, and research on retinitis pi...

Read more

Mineralys Therapeutics Announces First Patient Dosed in the ADVANCE-HTN Pivotal Trial of Lorundrostat for the Treatment of Uncontrolled and Resistant Hypertension

by Ysios Capital

Mineralys Therapeutics today announced the first patient dosed in the ADVANCE-HTN pivotal trial to evaluate the safety and efficacy of lorundrostat for the treatment of uncontrolled hypertension (uHTN...

Read more

Sant Pau empieza a administrar un nuevo medicamento CAR-T, de producción propia, contra linfomas B

by Hospital de la Santa Creu i Sant Pau

El Instituto de Investigación del Hospital de la Santa Creu i Sant Pau – IIB Sant Pau ha desarrollado un nuevo medicamento de inmunoterapia CAR-T que acaba de empezar a administrar, en el marco de ...

Read more

Palobiofarma announces a collaboration with the Foundation for Prader Willi Research (FPWR) for the development of PBF-999 as a novel treatment for the Prader Willi Research syndrome

by Palobiofarma

FPWR’s philanthropic investment will be used to partially fund Palobiofarma’s ongoing Phase 2 clinical trial to develop PBF-999 for the treatment of Prader Willi syndrome (PWS).

Read more
Subscribe to Directory
Write an Article

Recent News

Exposure to Heat and Cold During Pregnan...

The research team observed changes in head circumf...

Using mobile RNAs to improve Nitrogen a...

AtCDF3 gene induced greater production of sugars a...

El diagnóstico genético neonatal mejor...

Un estudio con datos de los últimos 35 años, ind...

Highlight

Eosinófilos. ¿Qué significa tener val...

by Labo'Life

​En nuestro post hablamos sobre este interesante tipo de célula del...

CataloniaBio & HealthTech se transforma ...

by CataloniaBio

CATALONIA.HEALTH es la nueva denominación que adopta a partir de hoy ...

Photos Stream